Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

November 8, 2015

 - Safety Profile Confirmed; Signs of Clinical and Biological Activity Observed; Recommended Phase 2 Dose Selected -

- Phase 1 Expansion Cohorts for Patients with IDH1 Mutant Positive Glioma, Cholangiocarcinoma, Chondrosarcoma and Other Advanced Solid Tumors Are Open and Enrolling -

UChicago and Evelo Therapeutics Partner to Advance Microbiome-based Cancer Immunotherapy

UChicago and Evelo Therapeutics Partner to Advance Microbiome-based Cancer Immunotherapy

November 9, 2015

Agreement to collaborate on development of microbiome-based cancer therapies to boost patients’ immune systems

Cambridge, Mass., November 9, 2015/PRNewswire/ – A partnership between Evelo Therapeutics and the University of Chicago will advance an immunotherapy that employs certain gut microbes to boost the immune system’s attack on cancer cells and improve the effectiveness of anti-cancer drugs.

Agios Reports Third Quarter 2015 Financial Results

Agios Reports Third Quarter 2015 Financial Results

November 5, 2015

 – New AG-221 and AG-120 Data in Solid Tumors and Hematologic Malignancies to be Presented at AACR-NCI-EORTC and ASH Annual Meeting –

Pronutria Biosciences Announces Jennifer Che, J.D., as Vice President, Intellectual Property Counsel

Pronutria Biosciences Announces Jennifer Che, J.D., as Vice President, Intellectual Property Counsel

November 5, 2015

Cambridge, Mass., November 5th, 2015 / BUSINESS WIRE / -- Pronutria Biosciences™ Inc., a biotechnology company pioneering a new class of therapeutics to mediate amino acid biology, announced today the appointment of Jennifer Che, J.D., as Vice President, Intellectual Property Counsel. Ms. Che will oversee all intellectual property activities related to the protection of Pronutria’s technology and lead candidates.

Acceleron Pharma Reports Third Quarter 2015 Financial and Operational Results

Acceleron Pharma Reports Third Quarter 2015 Financial and Operational Results

November 4, 2015

- ACE-083 Phase 1 results demonstrate an unprecedented increase in muscle volume. Phase 2 clinical trials planned to start next year -

- ACE-2494 generates significant increases in muscle mass in preclinical studies. Phase 1 clinical trial of ACE-2494 planned to start next year -

- FDA granted Fast Track Designation for dalantercept in combination with axitinib for the treatment of patients with advanced renal cell carcinoma -

Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer

Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer

November 4, 2015

Breakthrough Innovations from Flagship VentureLabs Target the Cancer Microbiome

Industry Leader Simba Gill Ph.D. Appointed CEO

Cambridge, Mass., Nov. 4, 2015/PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability, announced it has launched Evelo Therapeutics, a new company focused on leveraging the power of the microbiome to develop novel therapies for cancer, with an initial capital commitment of $35 million.

China Food and Drug Administration (CFDA) Grants Approval for Avedro’s KXL® System

China Food and Drug Administration (CFDA) Grants Approval for Avedro’s KXL® System

November 3, 2015

Avedro is the first and only company to receive CFDA approval for corneal cross-linking

T2 Biosystems Appoints Chief Commercial Officer

T2 Biosystems Appoints Chief Commercial Officer

November 3, 2015

LEXINGTON, Mass., Nov. 3, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced the appointment of veteran healthcare commercialization executive, David P. Harding, as the Company's chief commercial officer (CCO), effective immediately.

T2 Biosystems Announces Leading Hospitals Adopting T2Candida for Sepsis Detection

T2 Biosystems Announces Leading Hospitals Adopting T2Candida for Sepsis Detection

October 29, 2015

Adoption Driven by Need to Improve Sepsis Outcomes, Reduce Costs

TARIS Biomedical® Raises $32 Million and Expands Leadership Team and Board of Directors

TARIS Biomedical® Raises $32 Million and Expands Leadership Team and Board of Directors

October 27, 2015

TARIS® emerges, after the sale of its lead asset to Allergan, as a new company focused on developing a broad portfolio of urology products

Initial focus on bladder cancer and overactive bladder, using TARIS’ novel drug-device combination approach

Christopher Cutie, M.D., joins as VP, Clinical Development, and health care industry veterans Kevin Finney and Mark Iwicki join TARIS’ board of directors